Breaking News Instant updates and real-time market news.

AKCA

Akcea Therapeutics

$34.33

0.64 (1.90%)

09:33
08/07/18
08/07
09:33
08/07/18
09:33

Akcea Therapeutics price target raised to $46 from $33 at Wells Fargo

Wells Fargo analyst Jim Birchenough raised his price target for Akcea Therapeutics to $46 from $33 following review of Q2 operating results and ahead of expected approvals and global launches of two rare disease products as well as key pipeline updates. The analyst reiterates an Outperform rating on the shares.

  • 30

    Aug

  • 06

    Oct

AKCA Akcea Therapeutics
$34.33

0.64 (1.90%)

08/07/18
STFL
08/07/18
INITIATION
Target $33
STFL
Hold
Akcea Therapeutics transferred with a Hold at Stifel
Stifel transferred coverage of Akcea Therapeutics to analyst Paul Matteis, who set a Hold rating and $33 price target on the shares. His enthusiasm for their LICA antisense pipeline is balanced by his view that upcoming launches for Tegsedi in TTR Amyloidosis and Walyirva in Familial Chylomicronemia Syndrome could be below consensus, Matteis tells investors.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $50
PIPR
Neutral
Ionis approval narrower than expected, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says the European approval of Tegsedi announced this morning Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA) for the treatment of stage 1 or stage 2 polyneuropoathy in adult patients with hATTR was narrower than he originally expected. The indication is narrower than the broader hATTR patient population, inclusive of both cardiomyopathy and polyneuropathy, but makes sense considering that the pivotal trial primarily enrolled patients with stage 1 and 2 polyneuropathy, Van Buren tells investors in a research note. The analyst adds that while the approval is a positive development and Tegsedi represents the largest near-term pipeline opportunity for Ionis, he wants to observe positive early launch metrics and confirmation of the opportunity before getting more constructive on the shares. He keeps a Neutral rating on Ionis with a $50 price target.
05/11/18
WELS
05/11/18
UPGRADE
Target $33
WELS
Outperform
Akcea upgraded to Outperform with $33 target at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics to Outperform from Market Perform after an FDA panel voted 12-8 to support approval of Waylivra for the treatment of people with familial chylomicronemia syndrome. The analyst expects the vote to support approval of the drug by the August 30 action date. He raised his price target for Akcea shares to $33 from $30.
05/11/18
STFL
05/11/18
NO CHANGE
Target $25
STFL
Hold
Akcea clarity improved by panel vote, but challenges remain, says Stifel
Stifel analyst Stephen Willey said the FDA Advisory Committee's vote in favor of supporting the approval of volanesorsen improves the regulatory clarity for Akcea Therapeutics, but he believes commentary from both voting members and FDA reviewers would suggest there's still "tangible risk" to the formal FDA decision due on August 30. He has reduced his peak worldwide sales estimates to approximately $200M in an effort to better reflect the high proportion of patient discontinuations and dose-reductions occurring within clinical development, which lowered his price target on Akcea shares to $25 from $30. Willey keeps a Hold rating on the stock.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.